Skip to main content
. 2024 May 16;16:110. doi: 10.1186/s13195-024-01478-9

Fig. 3.

Fig. 3

Number of amyloid positive MCI subjects per arm for preventive clinical trials with different percentages of cognitive decline slowing considering the positivity of plasma biomarkers in subjects positive to Amy-PET only or combined with Tau-PET